900664
Poly(D,L-lactide-co-glycolide)(50:50)-b-poly(ethylene glycol)
10k-2k
Sinónimos:
PLGA-b-PEG, PLGA-PEG
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Fórmula lineal:
H[(C3H4O2)x(C2H2O2)y]mO[C2H4O]nCH3
Código UNSPSC:
12162002
NACRES:
NA.23
En este momento no podemos mostrarle ni los precios ni la disponibilidad
Productos recomendados
Categorías relacionadas
Aplicación
Biocompatible, amphiphilic block copolymer composed of a hydrophilic PEG block and a hydrophobic poly(D,L-lactide-co-glycolide) (PLGA) block. These materials have been used in control release and nanoparticle formulation for drug encapsulation and delivery applications. Well-defined materials with varying properties can be prepared by controlling the relative length of each polymer block. Hydroxyl termination allows for facile further chemical modification of these materials.
Código de clase de almacenamiento
11 - Combustible Solids
Clase de riesgo para el agua (WGK)
WGK 3
Punto de inflamabilidad (°F)
Not applicable
Punto de inflamabilidad (°C)
Not applicable
Elija entre una de las versiones más recientes:
Certificados de análisis (COA)
Lot/Batch Number
¿No ve la versión correcta?
Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Los clientes también vieron
Yihan Xu et al.
Journal of biomedical materials research. Part B, Applied biomaterials, 105(6), 1692-1716 (2016-04-22)
Poly (lactic-co-glycolic acid) (PLGA) copolymers have been broadly used in controlled drug release applications. Because these polymers are biodegradable, they provide an attractive option for drug delivery vehicles. There are a variety of material, processing, and physiological factors that impact
R Gref et al.
Science (New York, N.Y.), 263(5153), 1600-1603 (1994-03-18)
Injectable nanoparticulate carriers have important potential applications such as site-specific drug delivery or medical imaging. Conventional carriers, however, cannot generally be used because they are eliminated by the reticulo-endothelial system within seconds or minutes after intravenous injection. To address these
Fabienne Danhier et al.
Journal of controlled release : official journal of the Controlled Release Society, 133(1), 11-17 (2008-10-28)
The purpose of this study was to develop Cremophor EL-free nanoparticles loaded with Paclitaxel (PTX), intended to be intravenously administered, able to improve the therapeutic index of the drug and devoid of the adverse effects of Cremophor EL. PTX-loaded PEGylated
Miles A Miller et al.
Nature communications, 6, 8692-8692 (2015-10-28)
Therapeutic nanoparticles (TNPs) aim to deliver drugs more safely and effectively to cancers, yet clinical results have been unpredictable owing to limited in vivo understanding. Here we use single-cell imaging of intratumoral TNP pharmacokinetics and pharmacodynamics to better comprehend their
Artículos
The development of drugs that target specific locations within the human body remains one of the greatest challenges in biomedicine today.
Active Filters
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico
